Beroterkib

N/A

Report date: 2025/12/10 13:47:07
NME

Base Information

Drug NameBeroterkib
Drug Alias NameASTX-029
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionExtracellular-signal-regulated kinase1 inhibitorsExtracellular-signal-regulated kinase 2 inhibitors
TargetsExtracellular-signal-regulated kinase1Extracellular-signal-regulated kinase 2
Therapy Area/IndicationsSolid tumoursMyeloproliferative DisordersMyelodysplastic Syndromes +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesUnited KingdomFrance +[4] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesAstex Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesMosaic Therapeutics LtdTaiho Oncology Inc
Inactive CompaniesThe University Of Texas MD Anderson Cancer CenterAstex Pharmaceuticals Inc
Active IndicationsSolid tumours
Inactive IndicationsMyeloproliferative DisordersMyelodysplastic SyndromesLeukemia, Myeloid, Acute

Other Information

ATC CodeN/A
Related LinksN/A